Dow Breaks 49,000 as Oil, Gold and AI Giants Lead Wall Street’s 2026 Kickoff – January 5, 2025 -( $BTC $DV $EPRX $META $MODD $MTWO $OKLO $OPEN $PLTR $RIO $SOAR $SPY Rise!)

As the opening week of 2026 trading gathers steam, investors seem content to embrace risk—so long as the Fed stays predictable, Congress keeps the lights on, and oil, gold and bitcoin provide just enough drama to keep everyone awake at the morning meeting.. Yes indeed, Wall Street kicked off the first full week of 2026 with a risk‑on flourish Monday, as investors cheered record highs in blue chips, a firmer economy, and the comforting notion that the Federal Reserve will do absolutely nothing—at least for a few more weeks.

Indexes: Blue Chips Take a Victory Lap

The major U.S. benchmarks finished broadly higher, with the old‑economy stalwarts happily reminding Silicon Valley who actually rings the opening bell.

• The S&P 500 added 56.55 points, up about 0.64%, leaving the benchmark just a step below its late‑December record as money continued to favor quality large caps over speculative froth..
• The Dow Jones Industrial Average climbed roughly 594.79 points, a gain of 123.%, briefly trading above the 49,000 mark and logging its first record territory of 2026 as energy, financials and defense names rode geopolitics and higher oil.
• The Nasdaq Composite rose about 160 points, or 0.69%, as mega‑cap techs participated but ceded leadership to more cyclical and value‑tilted pockets of the market.
• The small‑cap Russell 2000 advanced roughly 1.58% to 2.557.92, extending an early‑year catch‑up trade that suggests investors are at least flirting with the idea of a broader economic upswing.

Macro, Fed and Washington

With the data calendar slowly normalizing after the record shutdown that ended in November, investors digested the first bits of 2026 macro noise and refocused on the Fed’s next move—or lack thereof.

• Monday’s U.S. ISM manufacturing reading was on tap as the marquee release, coming in the wake of an extended holiday lull and delayed government statistics, offering an early look at how industry is handling tighter financial conditions and new tariff realities.
• The yield curve remained stubbornly elevated, with the 10‑year Treasury yield hovering just above 4%, reflecting a “higher‑for‑longer” mindset in markets even after three rate cuts in late 2025.

The Federal Reserve, meanwhile, is in no hurry to play Santa in January.

• The federal funds rate sits in a 3.50%–3.75% range, and futures markets assign a high probability that the Fed will stand pat at its next FOMC meeting scheduled for January 27–28, setting up a policy “non‑event” but potentially eventful press conference.
• With inflation running near 2.4% and unemployment around 4.6%, policymakers are signaling a preference for “measured caution” as Chair Powell heads into the final months of his term, even as speculation builds over a Trump‑era successor.

In Washington, the government is open for business—for now.

• After a record‑long shutdown that ended in mid‑November, Congress is staring down a January 30 funding deadline, and lawmakers unveiled a roughly $174 billion spending bill aimed at avoiding a repeat performance.
• While key leaders in both parties say they want to avert another stoppage, the risk of brinkmanship remains, ensuring the phrase “shutdown odds” will stay in every strategist’s macro note this month.

Tariffs also remain very much part of the 2026 script.

• The U.S. collected roughly $187 billion more in tariff revenue in 2025 than in 2024, a near‑200% increase that is beginning to filter through to corporate planning, supply chains and, ultimately, pricing power.
• Research from the Federal Reserve’s San Francisco branch suggests that last year’s 15% jump in average U.S. tariffs may dampen inflation at the cost of higher unemployment, a policy trade‑off that markets will continue to game as new measures roll through.

FOMC, Rates and the Yield Curve

The rate narrative for early 2026 is less about cuts and more about staying power.

• After 2025’s gradual easing, economists expect the policy path in 2026 to see only modest reductions from the current 3.50%–3.75% fed‑funds range, keeping real rates restrictive enough to lean against asset bubbles without deliberately inviting recession.
• The yield curve remains compressed but no longer in the extreme inversion seen earlier in the cycle, with the 10‑year near 4.19% and shorter tenors anchored closer to the Fed’s target, signaling a market still unconvinced of rapid disinflation or imminent aggressive easing.

The FOMC calendar is now fully populated for the year.

• Policymakers will meet eight times in 2026, starting with the late‑January gathering, and investors will parse not just the statement but any hints about the process of choosing Powell’s successor ahead of his May 15 term expiration.
• Fed communications this week, including scheduled speeches, are expected to hew to the message that recent cuts were sufficient for now, with officials emphasizing data dependence and the need to keep inflation trending firmly toward the 2% target before contemplating a new easing cycle.

Commodities and Crypto: Oil in the Spotlight

Geopolitics ensured commodities stole a sizable chunk of Monday’s spotlight.

• Crude oil prices climbed to $58.35/bbl as markets digested the U.S. capture of Venezuela’s Nicolás Maduro and President Trump’s pledge that American drillers will help revive the country’s output, boosting energy shares and feeding the Dow’s outperformance.​
• Traditional safe havens caught a bid, with gold up about 3% to $4,459.70/oz. and silver surging nearly 7.75% to $76.51/oz,, moves that underscored lingering anxiety over geopolitical flare‑ups and policy uncertainty even as equities rallied.

Digital gold tried to join the party.

• Bitcoin (BTC, ~$94,297.38) extended a nascent rebound and was on track for its longest daily winning streak in three months, as some strategists floated the possibility of fresh all‑time highs by the end of January despite a bruising drawdown from last year’s peak.
• The broader narrative pits strong performance in physical metals against a more volatile crypto backdrop, with several year‑ahead outlooks anticipating further strength in gold and silver while characterizing bitcoin’s path as higher but far more turbulent.

Corporate Highlights: AI Darlings, Chips and Old‑School Brands

Tech and AI‑linked names remained central to the market conversation, even as leadership rotated.

• Eli Lilly (LLY) spent the day under the microscope of growth and healthcare investors, with attention still firmly on its obesity and diabetes franchises as analysts framed the stock as a long‑duration cash‑flow machine tied to GLP‑1 adoption.
• NVIDIA (NVDA) and Micron Technology (MU) traded as the market’s preferred AI arms dealers, with Micron increasingly cast as “the NVIDIA of AI memory” thanks to surging demand for high‑bandwidth DRAM needed in next‑generation data centers.
• Taiwan Semiconductor Manufacturing (TSM) and Intel (INTC) remained central to the semiconductor supply‑chain discussion, with Wall Street focusing on advanced packaging, foundry diversification and the political premium now embedded in leading‑edge capacity.
• Intel, in particular, drew fresh attention from bullish commentary highlighting its manufacturing roadmap and partnerships, with some strategists arguing that a more supportive U.S. policy backdrop could materially improve its long‑term earnings power.

The mega‑cap platform names stayed in every AI deck.

• Apple (AAPL) and Meta Platforms (META, $658.79, +1.29%) were held up as core beneficiaries of AI‑enhanced devices and advertising tools, with fresh buy‑and‑hold arguments pointing to their ability to monetize user data, ecosystem lock‑in and new services tied to generative models.
• Palantir Technologies (PLTR, $174.04, +3.68%) continued to attract attention as an AI‑data “picks and shovels” play, cited by multiple analysts as a long‑term beneficiary of rising defense, government and enterprise spending on intelligent decision systems.

The chip and infrastructure stack stayed busy.

• Broadcom (AVGO) featured prominently on AI watchlists as a beneficiary of accelerating demand for custom accelerators and networking silicon that sit behind massive language‑model training runs.
• Nokia (NOK) remained in focus as investors assessed how the 5G investment cycle and enterprise networking will interact with AI‑driven traffic growth, even as the stock continues to trade more like a value industrial than a high‑beta tech name.

Old‑economy icons still had their moment.

• McDonald’s (MCD) drew interest as a textbook consumer‑staple‑plus‑real‑estate story, with investors weighing its defensive qualities against any potential margin pressure from wage, food‑cost and tariff dynamics.
• Rio Tinto Group (RIO, $83.21, +2.19%) traded as a proxy for global growth and the critical‑minerals theme, with its exposure to iron ore, copper and other inputs keeping it central to conversations about re‑shoring, electrification and China’s still‑uncertain trajectory.

Software and data‑center plays remained on the front foot.

• Oracle (ORCL) stayed in the AI‑infrastructure limelight as it doubles its data‑center footprint and positions its cloud platform as a neutral venue for multiple AI models and GPU types, with a swelling remaining‑performance‑obligation backlog seen as a prelude to faster revenue growth.

In the more speculative corner of the tape, risk appetite remained intact.

• OKLO ($89.34, +14.83%), the advanced nuclear player, sat firmly in the energy‑transition narrative as investors looked ahead to regulatory milestones and potential partnerships that could make small modular reactors a more mainstream asset‑class over the coming decade.
• Opendoor (OPEN, $6.32, +4.12%) continued to serve as a levered bet on the U.S. housing market, with its fortunes tied to the path of mortgage rates, inventory and the possibility that lower long‑term yields might eventually revive transaction volumes.

Deals, M&A and IPOs

The deal machine has not fully shifted into high gear yet, but expectations for a busy 2026 remain firmly in place.​

• Across sectors, bankers and strategists anticipate a “bumper” year for M&A and IPOs, with cash‑rich strategic buyers and private‑equity funds under pressure to deploy capital after a quieter stretch, especially in technology, industrials and healthcare.
• Industrial advisers note that recent tariff moves and re‑shoring incentives are nudging companies to acquire U.S. operations rather than build greenfield plants, a trend that is already boosting due‑diligence activity in manufacturing‑adjacent verticals.

On the new‑issue front, the pipeline is starting to thicken.

• Special‑purpose vehicle Art Technology Acquisition Corp. priced a 22‑million‑unit Nasdaq IPO at $10 per unit for gross proceeds of about $220 million, with trading scheduled to begin January 6 and warrants exercisable at $11.50, adding another blank‑check vehicle to the tech and financials hunting ground.
• In biotech, Aktis Oncology laid out terms for what is set to be the first sector IPO of 2026, planning to sell about 11.8 million shares at $16–$18 apiece, with potential proceeds north of $180 million and room to climb above $200 million if underwriters exercise their option.

Vista Partners Watchlist Updates

Modular Medical, Inc. (Nasdaq: MODD., $.3894, +1.17%), a leader in innovative insulin delivery technology targeting the $3 billion adult “almost-pumpers” diabetes market with user-friendly, affordable patch pumps, announced (Dec. 10) that it had priced an underwritten public offering (the “offering”) of 12,173,000 shares of its common stock and accompanying warrants to purchase 6,086,500 shares of its common stock. Each two shares of common stock are being offered and sold together with one accompanying warrant at a combined offering at a price of $0.77, yielding an effective price of $0.38 per share and $0.01 per warrant. The warrants will have an exercise price of $0.45 per share, are exercisable immediately upon issuance and will expire five years following the date of issuance. In connection with the offering, Modular Medical has granted the underwriter a 30-day option to purchase up to an additional 15% of common shares and/or warrants at the public offering price, less underwriting discounts and commissions. The over-allotment option may be elected with respect to, at the underwriter’s sole discretion, shares and warrants together, solely shares, solely warrants, or any combination thereof. Newbridge Securities Corporation is acting as the sole bookrunner for the offering. Assuming no exercise of the over-allotment option, the gross proceeds to the Company from the offering are expected to be approximately $4.68 million, before deducting underwriting discounts, commissions, and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund operations and for working capital and general corporate purposes, including capital expenditures.

On Nov. 17, Modular announced Institutional Review Board (“IRB”) approval to conduct an in-house study of its next-generation Pivot™ insulin delivery system using insulin on people with diabetes (the “Study”). Pursuant to U.S. Food and Drug Administration (“FDA”) regulations, an IRB is a group that has been formally designated to review and monitor biomedical research involving human subjects. The Study will simulate real-world conditions by delivering insulin to adult participants to gather critical data on device function and usability and obtain user feedback. Modular Medical’s Pivot tubeless patch pump aims to enhance accessibility for underserved patients with diabetes and drive market penetration and expansion.

On Nov. 14, Modular Medical announced the 510(k) premarket submission of its next generation Pivot™ tubeless patch pump to the U.S. Food and Drug Administration (the “FDA”). The Company expects to commence the commercial launch of its Pivot pump in Q1 2026. On Nov. 3, Modular Medical the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, $7.68, +1.45%), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 13) the second set of 52-week follow up data from its ongoing Phase 1b/2a RESOLVE trial evaluating a single administration EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). James A. Helliwell, Chief Executive Officer of Eupraxia stated,“These data further highlight the strong durability and tolerability profile of EP-104GI, reinforcing its potential to become a convenient, once-a-year treatment that fits seamlessly into routine disease management by aligning with annual patient endoscopies. The Cohorts 5 & 6 patients – the only groups to have reached 52 weeks in the trial – are demonstrating levels of symptom relief that is durable and clinically meaningful – we are very encouraged by this outcome. We’re also pleased that our previously announced 52-week data were presented as a late-breaking presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG). These new results build on that momentum. Given that current EoE therapies often struggle with long-term adherence, we believe a durable, once-yearly treatment could meaningfully improve patient outcomes and establish EP-104GI as a preferred option for both physicians and their patients.”

GeoVax Labs, Inc. (Nasdaq: GOVX, $.19), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, announced (Dec. 19) that it has entered into definitive securities purchase agreements with several institutional and individual investors for the purchase and sale of approximately 13.2 million units, each comprised of one share of the Company’s common stock and warrants, as described below, to purchase shares of the Company’s common stock, at a price of $0.245 per unit in a public offering. The Company will issue warrants to purchase up to approximately 26.5 million shares of common stock. The warrants will have an exercise price of $0.245 per share, will be exercisable immediately following the date of issuance and will have a term of five years following the date of issuance. Roth Capital Partners is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering are expected to be approximately $3.2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. The closing of the offering is expected to occur on or about December 22, 2025, subject to the satisfaction of customary closing conditions.

GeoVax announced (Dec. 18) the publication of a peer-reviewed article in Frontiers in Immunology titled: “Multi-antigen MVA-vectored SARS-CoV-2 vaccine, GEO-CM04S1, induces cross-protective immune responses to ancestral and Omicron variants.” The study provides definitive preclinical evidence that GeoVax’s multi-antigen COVID-19 vaccine candidate, GEO-CM04S1, delivers full cross-variant protection, driven predominantly by robust T-cell responses, even in the absence of neutralizing antibodies. The findings reinforce the design philosophy behind GeoVax’s MVA-based, multi-antigen platform and provide mechanistic insight that is increasingly relevant for immunocompromised individuals, who often fail to respond optimally to the first-generation COVID-19 vaccines.

GeoVax announced (Dec. 17) the successful completion of fill-finish for the initial clinical batch of GEO-MVA, its next-generation Mpox/smallpox vaccine. The product has now entered final release evaluation, the concluding quality-control and compliance process required before shipment for clinical use, positioning the Company for Phase 3 immunobridging trial start-up activities in Q1 2026. Fill-finish – the sterile, cGMP-regulated process of filling, sealing, and packaging vaccine vials – marks the last manufacturing step before a vaccine may enter clinical study supply channels. With fill-finish complete and GEO-MVA now undergoing final release evaluation, GeoVax has moved into the final pre-clinical-deployment phase of its EMA-aligned clinical program. In June 2025, the European Medicines Agency (EMA) Scientific Advice confirmed that a single Phase 3 immunobridging study demonstrating immune comparability to the approved MVA vaccine, Imvanex(R), would be sufficient to evaluate GEO-MVA’s efficacy. This provides a clear, accelerated regulatory path to licensure. This milestone coincides with increasing Mpox activity globally – including expanding Clade I outbreaks in Africa and emerging cases in the United States – exposing vulnerabilities associated with global dependence on a sole foreign MVA vaccine supplier. GEO-MVA is designed to expand supply, diversify sources, and strengthen biodefense infrastructure.

Volato Group, Inc. (NYSE American: SOAR, $.72, +7.54%) and M2i Global, Inc. (MTWO, $.073, +5.42%), a company specializing in the development and execution of a complete global value supply chain for critical minerals, recently announced key developments in its pending all-stock merger with M2i Global, Inc.. Volato has filed the Registration Statement on Form S-4 with the U.S. Securities and Exchange Commission (the “SEC”), following the SEC’s completion of its review of the initial confidential submission. With the reopening of federal agencies following the recent government shutdown, both companies now anticipate closing the merger in the first quarter of 2026, pending completion of SEC review and shareholder approval.

Volato Group, Inc. today (Dec. 29) announced the appointment of Alan D. Gaines to its Board of Directors, effective immediately. Mr. Gaines will also serve as Chairman of the Audit Committee.

On Dec. 23, Volato Group, Inc. announced preliminary financial guidance for the fourth quarter and full year ending December 31, 2025, reflecting continued execution against its strategic and balance sheet objectives. For the fourth quarter of 2025, Volato expects to report revenue between $27 million and $28 million. For the full year 2025, the Company anticipates total revenue between $78 million and $79 million, with net income of $6 million to $8 million. These results reflect a year of meaningful progression aligning operational performance with Volato’s long-term growth initiatives and advancing its pending merger with M2i Global, Inc. (OTC: MTWO). During 2025, Volato also made substantial progress strengthening its balance sheet. As of September 30, 2025, the Company reduced total liabilities to $9.5 million, satisfying the debt reduction condition required under its pending merger agreement with M2i Global, Inc. (OTC: MTWO). Volato expects continued improvement in its capital structure as it advances toward a targeted first-quarter 2026 closing of the transaction. “Our 2025 results reflect a year of transformation and disciplined balance sheet execution,” said Mark Heinen, Chief Financial Officer of Volato. “We made significant progress reducing liabilities while sharpening our focus on scalable, technology-driven businesses that are designed to complement and strengthen the M2i Global platform over the long term.”

On Dec. 18, Volato Group, Inc. and M2i Global, Inc. announced that they applaud the recent December 11, 2025 announcement from the U.S. Department of State whereby Pax Silica, a U.S.-led strategic initiative to build a secure, prosperous, and innovation driven silicon supply chain—from critical minerals and energy inputs to advanced manufacturing, semiconductors, AI infrastructure, and logistics, was formed.

Volato Group, Inc. announced recently that it has set a preliminary date of February 26, 2026 and preliminary record date of January 17, 2026 for a special meeting of shareholders to vote on the proposed merger with M2i Global, Inc. (MTWO) and related matters. The preliminary meeting date and record date remain subject to applicable regulatory and exchange requirements, including the effectiveness of Volato’s Registration Statement on Form S-4 (File No. 333-292132) (the “Registration Statement”) filed with the U.S. Securities and Exchange Commission (“SEC”) and the mailing of definitive proxy materials to shareholders. The proposed merger creates a combined company built for scale. M2i Global brings a platform focused on critical minerals and national supply chain resilience, while Volato contributes proven aviation technology, software capability, and an established track record of operational execution. Together, the companies aim to participate in a U.S. critical minerals market estimated at more than $320 billion annually.

Serina Therapeutics (NYSE American: SER, $2.08, +.10%), Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies. On Dec. 11, Serina announced the appointment of Joshua Thomas, Ph.D., as Vice President and Head of Chemistry. He will oversee internal and external chemistry efforts to optimize POZ-based candidates, supporting efficient translation from discovery through development.

On Dec. 10, Serina announced that it has submitted a complete response to the U.S. Food and Drug Administration’s (“FDA”) clinical hold letter for SER-252, the Company’s lead program for advanced Parkinson’s disease. As previously disclosed, the FDA placed the Company’s Investigational New Drug (“IND”) application for SER-252 on clinical hold pending additional information related to a commonly used formulation excipient. On November 25, 2025, the FDA issued a formal full clinical hold letter specifying the information required to permit initiation of the planned Phase 1b registrational study, SER-252-1b. The issues identified by the FDA do not relate to the apomorphine active drug substance, its mechanism of action, the use of the enFuse device (Enable Injections) or the broader 505(b)(2) NDA development pathway previously discussed with the Agency.

The InterGroup Corporation (NASDAQ: INTG, $25.33) reported (Nov. 17) results for the three months ended September 30, 2025. John V. Winfield, Chairman and Chief Executive Officer, said: “We continue to observe signs of stabilization and recovery across the San Francisco hospitality market, including improving convention calendars, tourism indicators, and business travel activity. On the investment side, our marketable securities activity remained modest with a small net gain, consistent with our emphasis on liquidity and risk discipline.”

DoubleVerify Holdings Inc. (DV) closed at $11.14, +2.58%. DoubleVerify, which built its franchise on media verification and ad performance analytics, is now the first badged TikTok Marketing Partner focused specifically on attention measurement, tapping impression-level signals from the platform. Brands gain a granular view of how exposure and user interaction come together across TikTok formats, ad sets, creatives, and objectives, effectively treating every swipe as a tiny A/B test.

The Sources

1. https://markets.financialcontent.com/wral/article/marketminute-2026-1-5-the-powell-era-sunset-fed-braces-for-2026-transition-as-rate-cut-hopes-dim-for-january
2. https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-01-05-2026
3. https://www.seattlepi.com/business/how-major-us-stock-indexes-fared-monday-1-5-2026-a21277970
4. https://tvnewscheck.com/business/article/dow-climbs-595-nasdaq-adds-160-sp-500-rises-44/
5. https://www.barrons.com/livecoverage/stock-market-news-today-010526
6. https://www.thestreet.com/latest-news/stock-market-today-jan-5-markets-digest-venezuela-attacks-chipmaker-drama
7. https://fortune.com/2026/01/02/government-shutdown-january-deadline-federal-funding-agreement/
8. https://www.scotiabank.com/ca/en/about/economics/economics-publications/post.other-publications.calendar-of-economic-release-dates.calendar-of-economic-release-dates–january-2026-.html
9. https://tradingeconomics.com/calendar?article=29332&g=top&importance=2&startdate=2026-01-02
10. https://fred.stlouisfed.org/series/DGS10
11. https://www.federalreserve.gov/monetarypolicy/fomccalendars.htm
12. https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html
13. https://www.foxnews.com/politics/congress-rolls-out-174b-spending-bill-jan-30-shutdown-fears-grow
14. https://ctmirror.org/2026/01/05/congress-federal-shutdown-january-2026/
15. https://www.cnn.com/2026/01/05/politics/congress-aca-subsidies-vote-shutdown-ukraine
16. https://www.manufacturingdive.com/news/merger-acquisition-manufacturing-industrial-private-equity-tariff/804580/
17. https://www.cnn.com/2026/01/03/business/tariffs-prices-2026
18. https://seekingalpha.com/news/4536815-san-francisco-fed-research-suggests-that-higher-tariffs-could-reduce-inflation
19. https://tradingeconomics.com/united-states/interest-rate
20. https://www.ishares.com/us/insights/fed-outlook-2026-interest-rate-forecast
21. https://www.federalreserve.gov/releases/h15/
22. https://fred.stlouisfed.org/releases/calendar?ob=n&od=&y=&m=&rid=&vs=2026-01-05&ve=2026-01-05
23. https://alchemymarkets.com/education/market-insights/quarterly-forecast/q1-2026-crude-oil-silver-gold-bitcoin-forecast/
24. https://www.latimes.com/business/story/2026-01-05/wall-street-gains-ground-as-crude-prices-oil-company-stocks-rise-after-raid-on-venezuela
25. https://www.coindesk.com/markets/2026/01/05/bitcoin-eyes-longest-daily-winning-streak-in-3-months
26. https://www.forbes.com/sites/digital-assets/2025/12/27/us-dollar-collapse-crisis-warning-2026-gold-and-silver-surge-predicted-to-blow-up-the-bitcoin-price/
27. https://seekingalpha.com/article/4856778-5-predictions-for-2026-gold-silver-bitcoin-ai-geopolitics
28. https://www.fintechweekly.com/magazine/articles/bitcoin-gold-silver-relationship-outlook-2026-year-end-analysis
29. https://finviz.com/news/263255/5-stocks-set-to-start-strong-in-january-and-lead-through-2026
30. https://finance.yahoo.com/news/3-artificial-intelligence-stocks-buy-120500787.html
31. https://247wallst.com/investing/2025/12/18/3-stocks-to-watch-in-2026-as-ai-spending-becomes-a-hot-topic/
32. https://www.cnbc.com/2026/01/05/monday-biggest-wall-street-stocks-like-nvidia.html
33. https://www.aol.com/articles/5-tech-stocks-belong-january-145500211.html
34. https://www.marketbeat.com/instant-alerts/best-technology-stocks-to-keep-an-eye-on-january-4th-2026-01-04/
35. https://finance.yahoo.com/news/4-stocks-buy-january-could-132900449.html
36. https://www.theglobeandmail.com/investing/markets/stocks/ORCL/pressreleases/36824572/5-stocks-set-to-start-strong-in-january-and-lead-through-2026/
37. https://www.investing.com/analysis/5-stocks-set-to-start-strong-in-january-and-lead-through-2026-200672453
38. https://finance.yahoo.com/news/2026-set-bumper-m-ipos-112203546.html
39. https://www.stocktitan.net/news/ARTC/art-technology-acquisition-corp-announces-pricing-of-220-000-000-q2kj0p09fsu8.html
40. https://www.fiercebiotech.com/biotech/aktis-oncology-aims-209m-windfall-1st-biotech-ipo-2026
41. https://www.iposcoop.com
42. https://www.usatoday.com/story/news/politics/2026/01/05/will-government-shut-down-again/88030315007/
43. https://katv.com/news/nation-world/congress-enters-2026-with-a-packed-schedule-and-looming-funding-deadline-shutdown-venezuela-war-powers-epstein-files-affordable-care-act-subsidies
44. https://home.treasury.gov/resource-center/data-chart-center/interest-rates/TextView?type=daily_treasury_real_long_term&field_tdr_date_value=2025
45. https://247wallst.com/investing/2026/01/05/live-nasdaq-composite-markets-advance-despite-rising-geopolitical-headwinds/liveupdates/2/
46. https://www.reuters.com/business/us-stock-futures-make-positive-start-2026-risk-appetite-returns-after-recent-2026-01-02/
47. https://www.barchart.com/story/news/36893286/how-major-us-stock-indexes-fared-monday-1-5-2026
48. https://finance.yahoo.com/quote/%5EGSPC/history/
49. https://www.youtube.com/watch?v=3m4bW1fJ7P4
50. https://www.cstoredive.com/news/questions-c-store-industry-2026/808209/
51. https://www.youtube.com/watch?v=bxEAGvBTOJI
52. https://www.nasdaq.com/articles/3-artificial-intelligence-stocks-buy-2026-could-be-better-picks-palantir
53. https://www.marketwatch.com/story/techs-biggest-bull-lists-his-top-5-ai-stocks-for-2026-and-nvidias-isnt-one-of-them-04659b93
54. https://www.nasdaq.com/market-activity/ipos
55. https://www.marketwatch.com/economy-politics/calendar
56. https://finance.yahoo.com/calendar/ipo?from=2178-01-29&to=2178-02-04&day=2026-01-05
57. https://www.bls.gov/schedule/2026/home.htm
58. https://www.nasdaq.com/articles/pre-market-most-active-jan-5-2026-alt-tsll-tqqq-nvda-intc-smr-mstx-pcg-cvx-nio-bbai-slb